Micronization enhances the protective effect of purified flavonoid fraction against postischaemic microvascular injury in the hamster cheek pouch

Clinical and Experimental Pharmacology and Physiology

Volumn 31, Issue 3, 2004, Pages 159-162

  Cyrino, Fátima Z G A ^a   Bottino, Daniel A ^a   Lerond, Laurence ^b   Bouskela, Eliete ^a  

^a STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

Cheek pouch; Hamster; Macromolecular permeability; Micronization; Micronized purified flavonoid fraction

Indexed keywords

DEXTRAN; FLAVANOID; FLUORESCEIN ISOTHIOCYANATE; LACTOSE;

ANESTHESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHEEK POUCH; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; HAMSTER; HEART MUSCLE REPERFUSION; MALE; MICROSCOPY; MICROVASCULAR ISCHEMIA; NONHUMAN; PERMEABILITY;

ADMINISTRATION, ORAL; ANIMALS; CAPILLARY PERMEABILITY; CHEEK; CRICETINAE; DIOSMIN; DRUG COMBINATIONS; HESPERIDIN; ISCHEMIA; MALE; MESOCRICETUS; MICROCIRCULATION; PARTICLE SIZE; PROTECTIVE AGENTS; REGIONAL BLOOD FLOW; REPERFUSION; REPERFUSION INJURY;

EID: 1542407476     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2004.03974.x     Document Type: Article

References (31)

1. Lerond L. Action of Daflon 500 mg on the principal inflammatory mediators. Phlebology 1994; 9 (Suppl. 1): 34-9.
2. Struckman JR. Clinical efficacy of micronized Daflon 500 mg: An overview. J. Vasc. Res. 1999; 36 (Suppl. 1): 37-41.
3. Pearson JD. Pathophysiological mechanisms involving leukocytes in chronic venous insufficiency. Prog. Appl. Microcirc. 1999; 23: 82-90.
4. Korthuis RJ, Gute DC. Pathophysiologic implications of leukocyte activation in chronic venous insufficiency. Medicographia 2000; 22: 123-32.
5. Dröge W. Free radicals in the physiological control of cell function. Physiol. Rev. 2002; 82: 47-92.
6. Manthey JA. Biological properties of flavonoids pertaining to inflammation. Microcirculation 2000; 7 (Suppl.): S29-34.
7. Kloner CA, Ganote CE, Jennings F. The 'no-reflow' phenomenon after temporary coronary occlusion in the dog. J. Clin. Invest. 1974; 54: 1496-508.
8. Menger MD, Steiner DR, Meßmer K. Microvascular ischemia- reperfusion in striated muscle. Significance of 'reflow paradox'. Am. J. Physiol. 1992; 263: H1901-6.
9. Bouskela E, Donyo KA. Effects of oral administration of purified micronized flavonoid fraction on increased microvascular permeability induced by various agents and on ischemia/reperfusion in the hamster cheek pouch. Angiology 1997; 48: 391-9.
10. Korthuis RJ, Gute DC. Postischemic leukocyte/endothelial cell interactions and microvascular barrier dysfunction in skeletal muscle. Cellular mechanisms and effect of Daflon 500 mg. Int. J. Microcirc. Clin. Exp. 1997; 17 (Suppl. 1): 11-17.
11. Nolte D, Pickelmann S, Mollman M et al. Effects of the phlebotropic drug Daflon 500 mg on postischemic microvascular disturbances in striated skin muscle: An intravital microscopic study in the hamster. J. Lab. Clin. Med. 1999; 139: 526-35.
12. Bouskela E, Cyrino FZGA, Lerond L. Leukocyte adhesion after oxidant challenge in the hamster cheek pouch microcirculation. J. Vasc. Res. 1999; 36 (Suppl. 1): 11-14.
13. Bouskela E, Donyo KA, Verbeuren TJ. Effects of Daflon 500 mg on increased microvascular permeability in normal hamsters. Int. J. Microcirc. Clin. Exp. 1995; 15 (Suppl. 1): 22-6.
14. Takase S, Delano FA, Lerond L, Bergan JJ. Schmid-Schöbein GW. Inflammation in chronic venous insufficiency: Is the problem insurmountable? J. Vasc. Res. 1999; 36 (Suppl. 1): 3-10.
15. Duling BR. The preparation and use of the hamster cheek pouch for studies of the microcirculation. Microvasc. Res. 1973; 5: 423-9.
16. Svensjö E, Arfors KE, Arturson G, Rutili G. The hamster cheek pouch preparation as a model for studies of macromolecular permeability of the microvasculature. Uppsala J. Med. Sci. 1978; 83: 71-9.
17. Bouskela E, Grampp W. Spontaneous vasomotion in the hamster cheek pouch arterioles in varying experimental conditions. Am. J. Physiol. 1992; 262: H478-85.
18. Persson NH, Erlansson M, Svensjö E, Takolander R, Bergqvist D. The hamster cheek pouch: An experimental model to study postischemic macromolecular permeability. Int. J. Microcirc. Clin. Exp. 1985; 4: 257-63.
19. Friesenecker B, Tsai A, Allegra C, Intaglietta M. Oral administration of purified micronized flavonoid fraction suppresses leukocyte adhesion in ischemia/reperfusion injury: In vivo observations in the hamster skinfold. Int. J. Microcirc. Clin. Exp. 1994; 14: 50-5.
20. Coleridge-Smith PD. The microcirculation in venous hypertension. Cardiovasc. Res. 1996; 72: 789-95.
21. Pickelmann S, Nolte D, Leiderer R, Mollmann M, Schultze E, Meßmer K. Effects of the phlebotropic drug Daflon 500 mg on postischemic reperfusion injury in striated skin muscle: A histomorphologic study in the hamster. J. Lab. Clin. Med. 1999; 134: 536-45.
22. Hultström D, Svensjö E. Intravital and electron microscopic study of bradykinin-induced vascular permeability changes using FITC-dextran as a tracer. J. Pathol. 1979; 129: 125 (Abstract).
23. Persson CGA, Svensjö E. Vascular responses and their suppression: Drugs interfering with venular permeability. In: Bonta IL, Bray MA, Parnham MJ (eds). Handbook of Inflammation. The Pharmacology of Inflammation, Vol. 5. Elsevier, Amsterdam. 1985; 61-82.
24. He P, Curry FE. Depolarization modulates endothelial cell calcium influx and microvessel permeability. Am. J. Physiol. 1991; 261: H1246-54.
25. Bertuglia S, Colantuoni A, Intaglietta M. Effect of leukocyte adhesion and microvascular permeability on capillary perfusion during ischemia-reperfusion injury in the hamster cheek pouch. Int. J. Microcirc. Clin. Exp. 1993; 13: 13-26.
26. Erlansson M, Bergqvist D, Marklund SL, Persson NH, Svensjö E. Superoxide dismutase as an inhibitor of postischemic microvascular permeability increase in the hamster. Free Radic. Biol. Med. 1990; 9: 59-65.
27. Johnston AM, Paul HJ, Young CG. Effects of micronization on digestive absorption of diosmin. Phlebology 1994; 6 (Suppl. 1): 4-6.
28. 14C-diosmin tablets after oral administration to healthy volunteers by accelerator mass spectrometry and liquid scintillation counting. J. Pharm. Sci. 2002; 91: 32-40.
29. Cospite M, Dominici A. Advantages de la micronisation de Daflon 500 mg par rapport à une diosmine simple dans le traitement de l'insuffisance veineuse. Etude en double aveugle. Phlébologie 1998; 51: 243-7.
30. Cospite M, Milio G. Overview of pharmacological treatment of acute hemorrhoids. Phlebolymphology 2001; 31: 10-15.
31. Verbeuren TJ, Vallez MO, Rupin A et al. New synthetic diosmetin derivatives: Effects on different experimental models of the microcirculation. Prog. Appl. Microcirc. 1999; 23: 104-13.